Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Betacoronavirus Adaptation to Humans Involved Progressive Loss of Hemagglutinin-Esterase Lectin Activity.

Bakkers MJ, Lang Y, Feitsma LJ, Hulswit RJ, de Poot SA, van Vliet AL, Margine I, de Groot-Mijnes JD, van Kuppeveld FJ, Langereis MA, Huizinga EG, de Groot RJ.

Cell Host Microbe. 2017 Mar 8;21(3):356-366. doi: 10.1016/j.chom.2017.02.008.

2.

Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins.

Nachbagauer R, Choi A, Hirsh A, Margine I, Iida S, Barrera A, Ferres M, Albrecht RA, García-Sastre A, Bouvier NM, Ito K, Medina RA, Palese P, Krammer F.

Nat Immunol. 2017 Apr;18(4):464-473. doi: 10.1038/ni.3684. Epub 2017 Feb 13.

3.

Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.

Tan GS, Leon PE, Albrecht RA, Margine I, Hirsh A, Bahl J, Krammer F.

PLoS Pathog. 2016 Apr 15;12(4):e1005578. doi: 10.1371/journal.ppat.1005578. eCollection 2016 Apr.

4.

Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses.

Wohlbold TJ, Nachbagauer R, Margine I, Tan GS, Hirsh A, Krammer F.

Vaccine. 2015 Jun 26;33(29):3314-21. doi: 10.1016/j.vaccine.2015.05.038. Epub 2015 May 28.

5.

Animal models for influenza viruses: implications for universal vaccine development.

Margine I, Krammer F.

Pathogens. 2014 Oct 21;3(4):845-74. doi: 10.3390/pathogens3040845. Review.

6.

An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans.

Krammer F, Jul-Larsen A, Margine I, Hirsh A, Sjursen H, Zambon M, Cox RJ.

Clin Vaccine Immunol. 2014 Aug;21(8):1153-63. doi: 10.1128/CVI.00272-14. Epub 2014 Jun 18.

7.

Divergent H7 immunogens offer protection from H7N9 virus challenge.

Krammer F, Albrecht RA, Tan GS, Margine I, Hai R, Schmolke M, Runstadler J, Andrews SF, Wilson PC, Cox RJ, Treanor JJ, García-Sastre A, Palese P.

J Virol. 2014 Apr;88(8):3976-85. doi: 10.1128/JVI.03095-13. Epub 2014 Jan 22.

8.

Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.

Hai R, Schmolke M, Leyva-Grado VH, Thangavel RR, Margine I, Jaffe EL, Krammer F, Solórzano A, García-Sastre A, Palese P, Bouvier NM.

Nat Commun. 2013;4:2854. doi: 10.1038/ncomms3854.

9.

H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge.

Krammer F, Margine I, Hai R, Flood A, Hirsh A, Tsvetnitsky V, Chen D, Palese P.

J Virol. 2014 Feb;88(4):2340-3. doi: 10.1128/JVI.03183-13. Epub 2013 Dec 4.

10.
11.

One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge.

Klausberger M, Wilde M, Palmberger D, Hai R, Albrecht RA, Margine I, Hirsh A, García-Sastre A, Grabherr R, Krammer F.

Vaccine. 2014 Jan 9;32(3):355-62. doi: 10.1016/j.vaccine.2013.11.036. Epub 2013 Nov 18.

12.

Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.

Margine I, Krammer F, Hai R, Heaton NS, Tan GS, Andrews SA, Runstadler JA, Wilson PC, Albrecht RA, García-Sastre A, Palese P.

J Virol. 2013 Oct;87(19):10435-46. doi: 10.1128/JVI.01715-13. Epub 2013 Jul 31.

13.

Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin.

Goff PH, Krammer F, Hai R, Seibert CW, Margine I, García-Sastre A, Palese P.

J Virol. 2013 Jul;87(14):8235-40. doi: 10.1128/JVI.01085-13. Epub 2013 May 22.

14.

Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies.

Krammer F, Pica N, Hai R, Margine I, Palese P.

J Virol. 2013 Jun;87(12):6542-50. doi: 10.1128/JVI.00641-13. Epub 2013 Apr 10.

15.

H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice.

Margine I, Hai R, Albrecht RA, Obermoser G, Harrod AC, Banchereau J, Palucka K, García-Sastre A, Palese P, Treanor JJ, Krammer F.

J Virol. 2013 Apr;87(8):4728-37. doi: 10.1128/JVI.03509-12. Epub 2013 Feb 13.

16.

Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity.

Margine I, Martinez-Gil L, Chou YY, Krammer F.

PLoS One. 2012;7(12):e51559. doi: 10.1371/journal.pone.0051559. Epub 2012 Dec 7.

17.

A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates.

Krammer F, Margine I, Tan GS, Pica N, Krause JC, Palese P.

PLoS One. 2012;7(8):e43603. doi: 10.1371/journal.pone.0043603. Epub 2012 Aug 23.

18.

NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge.

Pica N, Langlois RA, Krammer F, Margine I, Palese P.

J Virol. 2012 Oct;86(19):10293-301. doi: 10.1128/JVI.01131-12. Epub 2012 Jul 11.

19.

Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes.

Hai R, Krammer F, Tan GS, Pica N, Eggink D, Maamary J, Margine I, Albrecht RA, Palese P.

J Virol. 2012 May;86(10):5774-81. doi: 10.1128/JVI.00137-12. Epub 2012 Mar 7.

Supplemental Content

Loading ...
Support Center